Categories
Change Password!
Reset Password!
Rimegepant 75 mg, used as needed or every other day, is safe, well-tolerated, and widely preferred by patients for long-term acute migraine treatment.
A recent post-hoc analysis of a multicenter, open-label phase 2/3 trial confirms the long-term safety and tolerability of rimegepant 75 mg for the acute treatment of migraine, regardless of patients’ prior experience with triptans.
The trial assessed rimegepant given either every other day and as needed for 12 weeks, or as needed over 52 weeks. Volunteers included adults grouped into 5 subcategories based on their triptan history: current triptan users with no history of discontinuation, triptan-naïve individuals, and those with a history of 1, at least 1, or at least 2 discontinued triptans. Triptan failure was defined broadly, including reasons like poor effectiveness or tolerability.
Across all subgroups, the percentage of volunteers experiencing at least one adverse event (AE) ranged from 57.6% to 66.3%, while rimegepant-related AEs were reported in 17.7% to 23.2% of participants. Upper respiratory tract infection was the most common AE, reported in 7.7% to 9.5% of cases. Treatment discontinuation rates were low, ranging from 1.6% to 3.8%, illustrating favorable long-term tolerability.
Importantly, more than 75% of subjects in each subgroup reported preferring rimegepant over their previous migraine medications, highlighting patient satisfaction and perceived effectiveness. Rimegepant 75 mg, taken up to once daily for acute migraine management, was found to be safe, well-tolerated, and highly preferred by patients, including those new to triptans, those currently using them, and those who had previously discontinued triptans. These findings support rimegepant as a versatile option for a diverse range of migraine sufferers.
Cephalalgia
Rimegepant safety and patient-reported outcomes among triptan-naïve, triptan-using, and triptan-failure participants: Subgroup analysis of an open-label, multicenter study
Jessica Ailani et al.
Comments (0)